CiplaLUX:CIPLA 94 PEG Ratio is 2.84 as of Jun. 30, 2026, which is 10% above its 10-year median of 2.58. GuruFocus rates LUX:CIPLA with a GF Score™ of 94/100 and a GF Value™ of $19.69. The stock has 5 warning signs investors should review. Among 346 Drug Manufacturers companies, Cipla ranks worse than 62.43% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Cipla's PE Ratio without NRI is 31.48. Cipla's 5-Year EBITDA growth rate is 11.10%. Therefore, Cipla's PEG Ratio for today is 2.84.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Cipla's PEG Ratio or its related term are showing as below:
LUX:CIPLA'
s PEG Ratio Range Over the Past 10 Years
Min: 1.33 Med: 2.58 Max: 8.5
Current: 2.55
During the past 13 years, Cipla's highest PEG Ratio was 8.50. The lowest was 1.33. And the median was 2.58.
LUX:CIPLA's PEG Ratio is ranked worse than 62.43% of 346
companies
in the Drug Manufacturers industry
Industry Median: 1.695
vs LUX:CIPLA: 2.55
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Cipla (LUX:CIPLA) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Cipla PEG Ratio Related Terms
Cipla PEG Ratio Historical Data
* Premium members only.
The historical data trend for Cipla's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipla PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipla's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Cipla's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Cipla (LUX:CIPLA) has a PEG Ratio of 2.84 as of Jun. 30, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Cipla and its competitors. This is 10% above median its historical median of 2.58. Over the past decade, Cipla's PEG Ratio has ranged from 1.33 to 8.50. According to the industry distribution chart, Cipla ranks #216 out of 346 companies in the Drug Manufacturers industry, placing it in the top 62.4%.
Is Cipla's PEG Ratio too high?
Cipla's current PEG Ratio of 2.84 is 10% above median its 10-year median of 2.58. Over the past 10 years, this metric has ranged from a low of 1.33 to a high of 8.50. The Drug Manufacturers industry median PEG Ratio is 1.70. Cipla's value of 2.84 is 67.6% above this industry median. Based on the distribution chart, Cipla ranks #216 out of 346 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Cipla has a GF Score™ of 94/100, reflecting its overall financial health beyond just this single metric.
How does Cipla's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cipla ranks #216 out of 346 companies for PEG Ratio. This places Cipla in the lower half of its industry. The industry median PEG Ratio is 1.70. Cipla's value of 2.84 is 67.6% above this benchmark. Historically, Cipla's own PEG Ratio has ranged from 1.33 to 8.50 over the past decade. While the company's 10-year median is 2.58 vs. the industry median of 1.70, Cipla has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.70, based on 346 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipla's current PEG Ratio of 2.84 is 67.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Cipla and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipla's current PEG Ratio is 2.84, which is 10% above median its own 10-year median of 2.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipla stock overvalued right now?
Cipla (LUX:CIPLA) has a current PEG Ratio of 2.84. The stock's GF Value™ is $19.69, compared to a current price of $18.10 — trading 8.1% below its estimated fair value. The current PEG Ratio is 2.84, which is 10% above median its 10-year median of 2.58 and 67.6% above the Drug Manufacturers industry median of 1.70. Cipla's overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Cipla (LUX:CIPLA), the current PEG Ratio is 2.84 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cipla (LUX:CIPLA) Overvalued in 2026?
Based on GuruFocus' analysis, Cipla stock appears to be undervalued.
The current stock price of $18.10 is trading 8.1% below its estimated GF Value™ of $19.69.
Key valuation signals for LUX:CIPLA:
PEG Ratio: 2.84 (10% above median its 10-year median of 2.58)
GF Value™: $19.69 vs. price of $18.10 (8.1% below fair value)
Industry Position: 67.6% above the Drug Manufacturers median (#216 of 346)
No single metric tells the full story. See the LUX:CIPLA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.
94GF Score
Get the complete analysis for LUX:CIPLA
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:CIPLA has been successfully added to your 
